Wednesday 30 November 2016

New Report Covers US Market for Declotting Devices 2017 - MedCore

US Market Report for Declotting Devices 2017 - MedCore is a new market research publication announced by Reportstack. General Report Contents
• Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
• Market Drivers & Limiters for each chapter segment
• Competitive Analysis for each chapter segment
• Section on recent mergers & acquisitions
The Fistula First objective is to improve the quality of life and survival of hemodialysis patients through optimizing the selection of vascular access. The majority of patients will benefit most through AV fistula access. AV fistula lowers mortality rates, hospitalization and infection while minimizing costs. Increased AV fistula use will result in a greater demand for declotting device procedures. Peritoneal dialysis does not require the use of hemodialysis declotting devices. Thus, the trend towards peritoneal dialysis will erode the number of hemodialysis patients and the amount of hemodialysis equipment sold. The market share and use of hemodialysis declotting devices is projected to decrease proportional to the number of patients transitioning from hemodialysis to peritoneal dialysis. 
Lumen stenosis can occur due to the accumulation of thrombosis or plaque particles in a similar manner to peripheral arterial disease. The accumulation of these plaque particles has also been shown to cause calcification. Lumen stenosis is a considerable problem for both AV access surgical grafts and native fistulae because they have poor vessel patency. Due to their tendency to acquire blockages, AV access surgical grafts will require revascularization twice a year, and native fistulae will need to be cleared at least once a year.
Scope
2013-2023
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###

No comments:

Post a Comment